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BACKGROUND: Monitoring antibiotic use in hospitals
was recognised as a priority by the European Union in
1998. However, most hospitals in the Europe currently
have very limited prescribing information systems.
METHODS: We compared two methods direct pharma-
cist monitoring and computerised records of drug supply
to six acute medical wards. The main outcome measure
was the number of patients exposed to glycopeptides. The
computerised system calculated used the modal pre-
scribed daily dose (PDD) divided by the average duration
of an intravenous antibiotic treatment course. Direct
pharmacist monitoring used individual record forms for
each patient prescribed glycopeptides.
RESULTS: Compared to the reports submitted from
direct monitoring the computerised estimate indicated
60% more use of glycopeptides. Limitations of both
systems were identiﬁed: 1. the use of average durations
of IV treatment can over estimate the number of courses
prescribed as the true duration for speciﬁc antibiotics 
may be longer than the average used; 2. PDDs may vary
depending on patient co-morbidities; 3. Data collection
by the direct method may be incomplete due to variabil-
ity in stafﬁng levels; 4. Paper records make data entry,
analysis and feedback time consuming and slow. The
major added value of direct pharmacist monitoring is
information about compliance with hospital policies.
Supply data showed a two-fold increase in glycopeptide
use in 18 months. Of 133 patients with completed forms
99 (74%) received glycopeptides for an appropriate indi-
cation but 14 (11%) of prescriptions outwith the policy
had been approved by Microbiology or Infectious Dis-
eases, leaving only 20 (15%) inappropriate prescriptions.
CONCLUSIONS: Ward supply data provides a conve-
nient method for checking the completeness of direct
patient monitoring. Paper-based monitoring is slow to
process. As a consequence of this study, funding is being
sought to facilitate the analysis and feedback of direct
monitoring through a network of intranet linked termi-
nals across the hospital.
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LIFE EXPECTANCY PREDICTION OF HRT FOR
PRIMARY PREVENTION STRATEGIES IN POST-
MENOPAUSAL WOMEN
Perreault S, Levinton C
Montreal University, Montreal, QC, Canada
During the post-menopausal years, the long-term conse-
quences of estrogen loss, namely coronary heart disease
(CHD), osteoporosis and osteoporosis-related fractures,
have an important effect on a woman’s morbidity and
mortality. In absence of randomized trials that include
clinical endpoints for all preventive strategies, a decision-
model is useful to predict the effect of treatment.
OBJECTIVE: To predict life expectancy (YOL) taking
into account CHD, hip fracture and breast cancer risk
using a Markov model based on data from the literature
and Canadian health statistics.
METHODS: The model was used to compare predicted
YOL of HRT based on low and high risk factor proﬁles
post-menopausal women. Under scenario 1, we assume a
risk reduction of 35% after 5 years of HRT and of 40%
after 10 years of treatment; we also assume that HRT
have a 20% and 50% of hip fracture risk reduction after
5 years and 10 years of treatment, and ﬁnally the
increased risk of breast cancer was at 35% in women
taking HRT for ﬁve years or longer. Under scenario 2:
similar assumptions were done except that we assume a
1% increase of risk of CHD during the 2 years following
the initiation of HRT.
RESULTS: Predicted YOL for low risk of CHD, hip frac-
ture and breast cancer of women aged 45, 55, 65 and 75
years old were at 0.52, 0.24, 0.17 and 0.010 under 
scenario 1, and these values were at 0.47, 0.23, 0.16 and
0.02 for scenario 2. The corresponding ﬁgures for high
risk of CHD, hip fracture and breast cancer for women
aged 45, 55, 65 and 75 years old were at 1.65, 0.64,
0.014 and -0.11 for scenario 1, and at 1.99, 0.87, 0.12
and -0.22 for scenario 2, respectively.
CONCLUSION: We suggest that HRT initiation should
take into account the risk proﬁle of post-menopausal
women and their age.
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ECONOMIC ANALYSIS OF SILDENAFIL CITRATE
ADD-ON TO TREAT SSRI-INDUCED ERECTILE
DYSFUNCTION
Nurnberg HG1, Duttagupta S2
1University of New Mexico, Albuquerque, NM, USA; 2Pﬁzer
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OBJECTIVE: To compare the economic cost of adding
sildenaﬁl to treat selective serotonin reuptake inhibitor
(SSRI)-induced erectile dysfunction (ED) with the cost of
switching patients to another SSRI or discontinuing all
depression pharmacotherapy.
METHOD: Based on our “real world” experience at an
academic medical center, we performed an economic
analysis on a hypothetical cohort of 1000 patients taking
SSRIs. In our model, patients received SSRIs for an acute
period of 60 days followed by continuation treatment for
120 days. We employed several evidence-based assump-
tions and used standard costs of antidepressants, silde-
naﬁl, and unit costs for physician visits within a managed
care environment and cost-of-illness methodology to 
calculate the annualized cost of depression in the SSRI
discontinuation group.
RESULTS: In our model, after 6 months of SSRI treat-
ment, the sildenaﬁl add-on group had the lowest cost 
estimates ($112/patient/month) compared with the group
267Abstracts
that switched to another SSRI ($169/patient/month) and
the group that discontinued SSRIs ($335/patient/month).
Sensitivity analyses demonstrated that the physician 
(specialist) visit was the single most important cost 
component (range, $100–$760) in this hypothetical 
population.
CONCLUSION: Sildenaﬁl can be a cost-effective add-on
therapy to control SSRI-induced ED. Healthcare payers
should consider this when developing optimum treatment
strategies for men with depression.
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OBJECTIVES: The approval of sildenaﬁl citrate as the
ﬁrst effective oral therapy for the treatment of erectile
dysfunction (ED) was met with both anticipation of 
its potential beneﬁts and concern regarding its potential
costs to employers and health plans. Health plan execu-
tives and employer healthcare professionals were asked
to determine what effect adding sildenaﬁl to pharmacy
formularies had on pharmacy beneﬁt costs.
METHODS: Utilizing their own pharmacy and medical
claims data, a panel of health plan executives and
employer healthcare professionals determined the actual
cost increase incurred as well as other effects of adding
coverage of sildenaﬁl to pharmacy beneﬁts. Per member
per month (PMPM) cost was calculated as total cost to
the plan divided by total membership distributed over 12
months.
RESULTS: Panel members included three executives from
health plans with 93,000 to 15 million members and 5
wellness and beneﬁts specialists and corporate medical
directors from companies employing 6000 to 150,000
employees. Actual PMPM costs associated with sildenaﬁl
addition to pharmacy formularies were $0.04, $0.05 or
less, $0.09, and $0.21. Many of the companies sponsored
men’s health screening and educational programs in 
conjunction with introduction of sildenaﬁl coverage.
Adding sildenaﬁl coverage and increasing the focus on
men’s health was associated with an increased use of the
healthcare system by men resulting in earlier detection
and treatment of underlying conditions that may con-
tribute to ED including hypertension, diabetes, ischemic
heart disease, dyslipidemia, depression, and prostate
cancer.
CONCLUSIONS: Although estimates as high as $1
PMPM were predicted, actual costs of sildenaﬁl coverage
were $0.05 PMPM or less at several companies. Addi-
tionally, assessment of ED provided an important oppor-
tunity for physicians to screen their patients for other,
potentially serious medical conditions that otherwise may
have gone undetected. This earlier disease detection may
be associated with less expensive treatment and better
outcome.
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OBJECTIVE: Numerous models have attempted to cal-
culate the cost effectiveness (CE) of HRT in peri- and
post-menopausal women. These models have used differ-
ent methods, structure, assumptions and inputs. Conse-
quently they have produced varying results, which can
impede decision makers’ ability to clearly understand the
value of HRT. We developed standard evaluation scenar-
ios to control for cross-study variations in model struc-
ture, major assumptions and inputs in order to better
understand the CE of HRT.
METHODS: We evaluated 12 original models published
between 1980 and 2001 and reporting net cost per
LY/QALY saved. Eight standard scenarios, deﬁned using
age at initiation (<60 or >=60 years of age), duration of
therapy (<10 or >=10 years), and inclusion of breast
cancer and coronary heart disease (CHD), were compiled
to facilitate this evaluation. The data collected were then
analyzed within and across scenarios to detect common
trends in results.
RESULTS: When the only beneﬁt considered in the 
analysis was fracture prevention, the economic value of
HRT was dependent on the length and age of initiation
of therapy. CE was most favorable when HRT was 
initiated later in life and for long-term (>10 years)
therapy. Analyses including CHD beneﬁts considerably
improved the CE ratios of HRT, regardless of age of 
initiation and duration of therapy.
CONCLUSIONS: Though some trends were identiﬁed
with this method, we found the lack of consistency in
methodology and inputs among the analyses did not
provide a comprehensive evaluation of the economic
value of HRT. Speciﬁcally, previous studies rarely
included HRT’s impact on menopausal symptoms, and no
studies distinguished between the impacts of different
HRT agents, which vary in terms of compliance and 
tolerability. Inclusions of these issues will likely affect 
the CE ratios, especially for younger postmenopausal
women. Therefore, these inputs should be included in
future economic analyses.
